NCT04857632

Statin for Neuroprotection in Spontaneous Intracerebral Hemorrhage

• Status: Unknown
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 98 (estimated)
• Sponsor: Capital Medical University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Brain injury after spontaneous intracerebral hemorrhage results from pathophysiologic responses in the brain parenchyma due to hematoma formation, release of clot components, and surrounding edema. Inflammatory cascade activation in the perihematomal brain parenchyma has been implicated in the pathogenesis of secondary brain injury. Statins have been identified as a potential neuroprotective agent that targets the inflammatory response to intracerebral hemorrhage. In preclinical studies, statin treatment in animal intracerebral hemorrhage models has consistently demonstrated neuroprotective and recovery enhancement effects. Clinical investigations in humans reported better patient outcomes associated with statin use in patients with intracerebral hemorrhage, including reduced perihematomal edema, lower mortality rates, and improved functional outcomes.

Conditions

• Intracerebral Hemorrhage
• Statins

Interventions

Type	Name	Description
DRUG	Statin	atorvastatin 20mg per day for 7 days

Timeline

• Start date: 2021-08-06
• Primary completion: 2024-06-30
• Completion: 2024-11-30
• First posted: 2021-04-23
• Last updated: 2024-01-23

Locations

3 sites across 1 country: China